EGFR and non-small cell lung carcinoma: The study showed that in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation after platinum-based chemotherapy, the overall response rate after using amivantamab was 40%, and the median duration of response was 11.1 months, indicating a good clinical effect (101).